Back to search results

Kindred Web-Based Program for Genetic Cancer Risk in African American Families

This study is testing a web-based program called Kindred. It aims to help African American families better understand their genetic risk for cancer and the process of genetic testing. Some cancers, like those related to BRCA1, BRCA2, and Lynch Syndrome, run in families due to inherited genetic changes. If a genetic change is found in a family, other relatives can choose to get tested to learn their own cancer risk. This study wants to see if Kindred helps families understand this information. You can join if you are 18 or older and have recently been evaluated at the University of Michigan's Breast and Ovarian Cancer Risk Evaluation Clinic or Cancer Genetics Clinic for hereditary breast and ovarian cancer syndrome or Lynch Syndrome. The study will measure how many people join and stay in the program, and why they enroll.

Study design
This is an interventional study with a planned enrollment of 150 participants. It is not specified if it is randomized or blinded.
What's involved
You would receive access to the Kindred web-based portal, share information and invite relatives, and receive check-in calls. The duration of these activities is not specified.
Compensation
Not stated in the trial record.
Follow-up
The study will track recruitment, retention, and reasons for enrollment for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07542405

A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families

Not Yet Recruiting
NAAges 18+InterventionalHealth services
University of Michigan Rogel Cancer Center
~150 participants
Updated 2026-05-19 on ClinicalTrials.gov
What's tested:DiscussionInternet-Based InterventionSurvey AdministrationTelephone-Based Intervention

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recruitment rates (Feasibility)
Measured over Up to 2 years
+5 more outcomes measured

Conditions

BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome
BRCA2-Related Hereditary Breast and Ovarian Cancer Syndrome
Hereditary Neoplastic Syndrome
Lynch Syndrome

Explore related trials

BRCA1-Associated Hereditary Breast and Ovarian Cancer SyndromeBRCA2-Associated Hereditary Breast and Ovarian Cancer SyndromeHereditary Neoplastic SyndromeLynch SyndromeBRCA1 GeneBRCA2 GeneDNA Mismatch Repair Protein Mlh1EPCAM GeneMSH2 GeneMSH6 GenePMS2 Gene

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Katrina Ellis, MD · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center

Who to contact

Cacner AnswerLine
[email protected]
1-800-865-1125
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

PROBANDS: Evaluation in the past one-year at the Breast and Ovarian Cancer Risk Evaluation Clinic (BOCRE) or Cancer Genetics Clinic, both located at the University of Michigan (U-M) Rogel Cancer Center who are positive for hereditary breast and ovarian cancer syndrome (HBOC) (BRCA1, BRCA2) or Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM); indeterminate negative; or variants of uncertain clinical significance (VUS). If more than one biological relative is known to have received an evaluation for and or completed germline testing for cancer risk, the relative who was evaluated the longest time ago to align with the tradition definition of a proband as defined by the National Cancer Institute (NCI), i.e., the first person identified as possibility having a genetic disorder and who may receive counseling or testing
PROBANDS: \>= 18-years-old
PROBANDS: Completed genetic testing for hereditary cancer syndromes, regardless of results
PROBANDS: Able to speak and read English
PROBANDS: Access to the internet
PROBANDS: Identifies as African American or Black (may have additional race or ethnicity identities)
RELATIVES: Biological relative of enrolled proband, regardless of testing completion or timing of testing
RELATIVES: \>= 18 years old
RELATIVES: Able to speak and read English
RELATIVES: Access to the internet

Exclusion

PROBANDS: No evaluation at U-M or other facility, or evaluation was more than one year ago, or received an evaluation more recently than the relative
PROBANDS: Under 18-years-old
PROBANDS: Did not receive cancer genetic testing
PROBANDS: Does not speak or read English
PROBANDS: Does not have internet access
PROBANDS: Does not identify as African American or Black
RELATIVES: Not a biological relative of proband
RELATIVES: Under 18-years-old
RELATIVES: Does not speak or read English
RELATIVES: Does not have internet access

What this trial measures

  • Recruitment rates (Feasibility)Up to 2 years

    Will carefully monitor recruitment (refusals and enrollees, 20% of invited). As this is a single-arm pilot study, no formal hypothesis testing is planned. Qualitative data from focus groups will be conducted using directed content analysis in order to identity key findings and themes to inform intervention content and structure for a future clinical trial.

  • Retention rates (Feasibility)Up to 2 years

    Will carefully monitor retention (75% of enrolled). As this is a single-arm pilot study, no formal hypothesis testing is planned. Qualitative data from focus groups will be conducted using directed content analysis in order to identity key findings and themes to inform intervention content and structure for a future clinical trial.

  • Reasons for enrollment (Feasibility)Up to 2 years

    Will carefully monitor reasons for enrollment. As this is a single-arm pilot study, no formal hypothesis testing is planned. Qualitative data from focus groups will be conducted using directed content analysis in order to identity key findings and themes to inform intervention content and structure for a future clinical trial.

  • Reasons for ineligibility (Feasibility)Up to 2 years

    Will carefully monitor reasons for ineligibility. As this is a single-arm pilot study, no formal hypothesis testing is planned. Qualitative data from focus groups will be conducted using directed content analysis in order to identity key findings and themes to inform intervention content and structure for a future clinical trial.

  • Reasons for dropout and withdrawal (Feasibility)Up to 2 years

    Will carefully monitor reasons for dropout and withdrawal. As this is a single-arm pilot study, no formal hypothesis testing is planned. Qualitative data from focus groups will be conducted using directed content analysis in order to identity key findings and themes to inform intervention content and structure for a future clinical trial.

  • Ease and process of implementing study procedures (Feasibility)Up to 2 years

    Will carefully monitor ease and process of implementing study procedures. As this is a single-arm pilot study, no formal hypothesis testing is planned. Qualitative data from focus groups will be conducted using directed content analysis in order to identity key findings and themes to inform intervention content and structure for a future clinical trial.